FREE Shippingto US, AU, UK and EU on all orders over $149
Sold out
/

Instenon (30 coated tablets)

$9.40

Out of stock

c34581f01003

Description

The instruction for use

Instenon

the Trade name

of Instenon Mezhdunarodnoye the unlicensed name
Is not present medicine for experts

the Dosage form
of the Tablet, coated
Tablets forte, coated
Solution for intramuscular and intravenous injections of 2 ml

Structure
One tablet contains
active agents: etofillin 60 mg
etamivan 50 mg
Hexobendinum dihydrochloride of 20 mg,
excipients: magnesium stearate of 2.0 mg, talc of 4.0 mg, lactose of 10.0 mg, corn starch of 44.0 mg,
structure of a cover: sucrose of 34.33 mg, the titan dioxide of 0.47 mg, Hekhst wax E of 0.10 mg, povidone To 30 1.20 mg, a macrogoal of 6000 2.40 mg, arabic gum of 4.75 mg, talc of 26.75 mg.

One tablet forte contains
active agents: etamivan 100 mg
Hexobendinum dihydrochloride of 60 mg
etofillin 60 mg,
excipients: magnesium stearate of 3.0 mg, talc of 8.0 mg, lactose of 12.0 mg, corn starch of 47.0 mg,
structure of a cover: sucrose of 39.3 mg, the titan dioxide of 1.4 mg, color varnish sanst yellow – From 1.4 mg, Hekhst wax E of 0.1 mg, PVP To 30 1,4 mg, a macrogoal of 6000 2,8 mg, arabic gum of 5.6 mg, talc of 28.0 mg.

1 ml of solution contains
active agents: etofillin 50 mg
etamivana of 25 mg
Hexobendinum dihydrochloride of 5 mg,
excipients: sodium edetat, propylene glycol, water for injections.

The description
of the Tablet – round, coated white color with a plain brilliant surface and a kernel of white color.
Tablets forte – round, biconvex, coated orange color with a brilliant surface and a kernel of white color.
Solution for injections – colourless, transparent solution.

Pharmacotherapeutic group
Peripheral vazodilatator. Purines
the Code of automatic telephone exchange C04AD

the Pharmacological

Pharmacokinetics Action properties of drug of Instenon is cumulative action of its components therefore carrying out kinetic observations is not possible.

Instenon pharmacodynamics – is the combined drug for improvement of functions of a brain in the conditions of the broken blood-groove. Active components of drug affect in common, in one stage and unidirectionally various links of pathogenesis of ischemic and hypoxemic damage of nervous system.
Etofillin activates metabolism of a myocardium with increase in minute volume of heart that promotes increase in perfusion pressure in vessels of a regional area of ischemia. At the same time system arterial blood pressure does not change. Exciting action on nervous system is shown in stimulation of subcrustal formations, a midbrain and the stem centers and kernels (respiratory, vasomotor, the centers of vegetative regulation and also kernels of cranial nerves, first of all wandering).
Etamivan has the significant positive impact on adaptation opportunities of a reticular formation of a brainstem, normalizing a functional condition of neural complexes of bark and subcrustal and stem structures.
Hexobendinum increases utilization of glucose and oxygen due to activation of anaerobic glycolysis and pentozny cycles. Possibilities of such activation are implemented only in the conditions of ischemia and a hypoxia when the cycle of aerobic oxidizing phosphorylation is broken. Stimulation of anaerobic oxidation gives power substrate for synthesis and exchange of mediators, neurotransmitters and restoration of synoptic transfer which oppression, along with destruction of membranes of neurons, is the leading pathogenetic mechanism of disorders of consciousness and neurologic disturbances in a hypoxia and ischemia of a brain.Hexobendinum also stabilizes physiological mechanisms of an autoregulyation of a cerebral and cardial blood-groove that is connected with impact of a lactate and pyruvate (products of anaerobic glycolysis) on the prescription device of intracranial arterioles and capillaries.
At Instenon’s use in cases of an ischemic stroke, the closed craniocereberal injury the restoration of disturbance of consciousness of the patient, regression of neurologic disturbances, activation of the vegetative sphere is noted.

Indications
– diseases of a brain of vascular character
– acute disorders of cerebral circulation and their consequence
– chronic forms of cerebrovascular insufficiency
– encephalopathy of various genesis
– vegeto-vascular dystonia
– the dizzinesses caused by functional disorders of a brain
– parkinsonism of vascular origin

appoint the Route of administration and doses In acute cerebral ischemia and a hypoxia in/in by drop infusion slowly in a dose of 2 ml in 200 ml of 5% of solution of a dextrose (glucose) or normal saline solution. Frequency rate of use – 1-2 times a day. Duration of treatment is 3-5 days or before clinical improvement. In process of improvement of a state the treatment can be continued by oral forms of drug.
In other cases parenterally appoint in a single dose 2 ml in oil or in/in by drop infusion in 200 ml of 5% of solution of a dextrose, slowly. Frequency rate of introduction 1-2 times a day. Duration of treatment is 7-10 days.
At chronic cerebral insufficiency inside appoint 1-2 tablets 2-3 times a day or on 1 tablet forte of 3 times/days (at most 5 tablets). Duration of treatment has to be not less than 6 weeks. A pill is taken, without chewing, after a meal, washing down with a small amount of liquid.

Side effects
– headaches (at fast in in introduction)
– hyperaemia of the person

Contraindication tachycardia
– a convulsive syndrome
– the increased intracranial pressure
– intracerebral bleeding
– hypersensitivity to drug components

Medicinal interactions
At combined use of an instenon and acetylsalicylic acid is possible strengthening of its antiagregantny action.
Simultaneous use of an instenon and caffeine in high doses can lead to decrease in medical effect of an instenon.

Special instructions
In some cases at fast in/under the authority of drug the ABP can go down.
Pregnancy and a lactation
during pregnancy and breastfeeding appoint drug strictly according to indications if the expected advantage exceeds potential risk.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms.
Does not influence.

Overdose
At overdose headaches, tachycardia and hyperaemia of the person can be observed. In these cases the decrease in a dosage with the subsequent cancellation is recommended.

The form of release and packing
of the Tablet coated
On 10 tablets in the blister packing from aluminum foil and polymeric film No. 3.
Secondary packing – a cardboard box.
Tablets forte, coated
On 10 tablets in the blister packing from aluminum foil and polymeric film No. 5.
Secondary packing – a cardboard box.
Solution for injections
On 2 ml of solution in ampoules from colourless glass. 5 ampoules in polisterolovy packing.
Secondary packing – a cardboard box.

To store storage conditions of the Tablet in the place protected from light, at a temperature of +15-+25 s.
To store solution for injections in the place protected from light, at a temperature from +2 to +8C.
To store out of children’s reach!

An expiration date
of the Tablet of 5 years
Solution for injections 3 years
not to use after expiry date

Prescription status
According to the prescription

the Producer Nikomed Austria GmbH, Austria

Representation in RK Nikomed Ostevropa Marketing Service GmbH, Begalina 136 A, ph. 444 004, fax 444 005

Reviews

There are no reviews yet.

Be the first to review “Instenon (30 coated tablets)”

Your email address will not be published. Required fields are marked *